html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:24368434

L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis.

The American journal of clinical nutrition2014The record ↗

(R)-carnitine

lowersC-reactive protein concentration

What moved

1 findingHow to read these marks →

Decreases C-reactive protein concentration
very limitedreplicated ×3
“l-Carnitine significantly decreased serum low-density lipoprotein (LDL) (mean difference: -5.82 mg/dL; 95% CI: -11.61, -0.04 mg/dL) and C-reactive protein (CRP) (-3.65 mg/L; -6.19, -1.12 mg/L).”
Study
meta-analysis
Population
Adults with end-stage kidney disease on maintenance hemodialysis; meta-analysis of 49 randomized trials (1734 participants)

Study record

Design: meta-analysis
Species: human
Population: adults with end-stage kidney disease requiring maintenance hemodialysis
Participants: 1,734
Comparator: not stated in the paper
Duration: not reported
Endpoints measured: 9